CliffBio
small molecule

SESQUIENT

FOSPHENYTOIN SODIUM

Loss of exclusivityFebruary 2033latest FDA-listed patent expiry
CompanyLupin →View the full company profile on CliffBio

Drug detail

Brand nameSESQUIENT
Active ingredientFOSPHENYTOIN SODIUM
StrengthEQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalNovember 2020
Marketing statusDISCN

Listed patents

PatentExpiresType
9493582February 2033product
8410077March 2029product
9200088March 2029product
9750822March 2029product
7635773March 2029product

More from Lupin

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SESQUIENT patent cliff — loss of exclusivity February 2033 | CliffBio